Skip navigation
MedlinePlus Trusted Health Information for You U.S. National Library of MedicineNational Institutes of Health
Contact Us FAQs Site Map About MedlinePlus
español Home Health Topics Drug Information Medical Encyclopedia Dictionary News Directories Other Resources

Other drug names:  A-Am  An-Az  B  C-Ch  Ci-Cz  D-Dh  Di-Dz  E  F  G  H  I-J  K-L  M-Mh  Mi-Mz  N-Nh  Ni-Nz  O  P-Pl  Pm-Pz  Q-R  S-Sn  So-Sz  T-To  Tp-Tz  U-V  W-Z  0-9

Granisetron  (Systemic)

Printer-friendly versionE-mail this page to a friend
Contents of this page:

Brand Names

In the U.S.—

  • Kytril

In Canada—

  • Kytril

Category


Description

Granisetron ( gra-NI-se-tron) is used to prevent the nausea and vomiting that may occur after treatment with anticancer medicines (chemotherapy) or with radiation therapy.

Granisetron is to be given only by or under the immediate supervision of your doctor. It is available in the following dosage forms:



Before Using This Medicine

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For granisetron, the following should be considered:

Allergies—Tell your doctor if you have ever had any unusual or allergic reaction to granisetron, dolasetron, or ondansetron. Also tell your health care professional if you are allergic to any other substances, such as foods, preservatives, or dyes.

Pregnancy—Granisetron has not been studied in pregnant women. However, granisetron has not been shown to cause birth defects or other problems in animal studies.

Breast-feeding—It is not known whether granisetron passes into breast milk. Although most medicines pass into breast milk in small amounts, many of them may be used safely while breast-feeding. Mothers who are taking this medicine and who wish to breast-feed should discuss this with their doctor.

Children—This medicine has been tested in children 2 years of age and older and, in effective doses, has not been shown to cause different side effects or problems than it does in adults.

Older adults—This medicine has been tested in a limited number of patients 65 years of age or older and has not been shown to cause different side effects or problems in older people than it does in younger adults.

Other medicines—Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your health care professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Other medical problems—The presence of other medical problems may affect the use of granisetron. Make sure you tell your doctor if you have any other medical problems.


Proper Use of This Medicine

Dosing—

The dose of granisetron will be different for different patients. The following information includes only the average doses of granisetron.


Precautions While Using This Medicine

Check with your doctor if severe nausea and vomiting occur after receiving the anticancer medicine.


Side Effects of This Medicine

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor as soon as possible if any of the following side effects occur:

Other side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. However, check with your doctor if any of the following side effects continue or are bothersome:


Additional Information

Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not included in product labeling, granisetron injection is used in certain patients to prevent the nausea and vomiting that may occur after cancer radiation treatment in patients undergoing bone marrow transplantation.

Other than the above information, there is no additional information relating to proper use, precautions, or side effects for this use.


Developed: 12/16/1994
Revised: 08/15/2000

Micromedex, Inc. Disclaimer

Copyright© 2003 Thomson MICROMEDEX. All rights reserved. USP DI® and Advice for the Patient® are registered trademarks of USP used under license to Micromedex, a business of Thomson Healthcare Inc. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.